Evaluation of the Safety of Lead Compounds for Allergic Asthma

铅化合物治疗过敏性哮喘的安全性评价

• 批准号: nhmrc : GNT1122668
• 负责人: A/Pr Mark Smythe
• 金额: $ 31.06万
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/evaluation-safety-lead-allergic-asthma/1347291
• 关键词: Evaluation; Safety; Lead; Compounds; Allergic

Asthma is one of the most common chronic respiratory diseases in developed countries and is typically treated with corticosteroids which provide symptomatic relief and coarse non-specific treatment of the underlying disease. We are pursuing innovative therapies by targeting a different enzyme, HPGD2S, involved in the inflammatory mechanisms of asthma. We have developed potent, anti-inflammatory drug candidates and aim to profile the safety of these compounds before entering clinical studies.

哮喘是发达国家最常见的慢性呼吸道疾病之一，通常用皮质类固醇治疗，皮质类固醇提供症状缓解和基础疾病的粗略非特异性治疗。我们正在通过靶向参与哮喘炎症机制的不同酶HPGD 2S来寻求创新疗法。我们已经开发出有效的抗炎药物候选药物，并旨在在进入临床研究之前对这些化合物的安全性进行评估。